<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2409">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 14, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04780685</url>
  </required_header>
  <id_info>
    <org_study_id>STEM-107-COVID-19</org_study_id>
    <nct_id>NCT04780685</nct_id>
  </id_info>
  <brief_title>A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19</brief_title>
  <official_title>A Phase II, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Preliminary Efficacy of Intravenous Allogeneic Mesenchymal Stem Cells in Patients With Moderate to Severe ARDS Due to COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stemedica Cell Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>bioRASI, LLC</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stemedica Cell Technologies, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in&#xD;
      Patients with moderate to severe lung injury due to COVID-19 or other potential viral and&#xD;
      bacterial pathogens.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase II multi-center, double-blind, placebo-controlled, randomized study in&#xD;
      Patients with moderate to severe lung injury due to COVID-19 or other potential viral and&#xD;
      bacterial pathogens. The study will enroll up to 40 Patients into two cohorts, randomized 1:1&#xD;
      to receive active study drug plus standard treatment or placebo (LRS) plus standard&#xD;
      treatment. On the treatment (Day 0) Cohort 1 will receive a single IV dose of hMSCs Cohort 2&#xD;
      will receive Lactated Ringer's Solution. A second dose of MSCs or LRS will be given to Cohort&#xD;
      1 or Cohort 2, respectively on Day 3 after the first dose. Patients who discontinue the study&#xD;
      before Month 1 for reasons other than adverse events will be replaced.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 20, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>This is double-blind study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Survival</measure>
    <time_frame>14 days post treatment</time_frame>
    <description>Number of patients alive at day 14 post treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>9 months</time_frame>
    <description>Frequency of adverse events in patients treated with hMSCs and Lactate Ringer's solutions will be compared.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>hMSCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>hMSCs will be given via IV administration.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactated Ringer's Solution</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Lactated Ringer's Solution will be given via IV administration.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>hMSC</intervention_name>
    <description>IV administration</description>
    <arm_group_label>Lactated Ringer's Solution</arm_group_label>
    <arm_group_label>hMSCs</arm_group_label>
    <other_name>allogeneic mesenchymal bone marrow cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Laboratory-confirmed diagnosis of COVID-19 &lt;= 14 days prior to randomization&#xD;
&#xD;
          -  The presence of moderate to severe Acute Respiratory Distress Syndrome (ARDS) as&#xD;
             defined by the Berlin Definition:&#xD;
&#xD;
               1. Bilateral chest radiograph infiltrates.&#xD;
&#xD;
               2. PaO2:FiO2 ratio of less than 200.&#xD;
&#xD;
               3. Absence of other clinical conditions that could present in a similar manner&#xD;
                  (non-infectious pneumonitis, cardiogenic pulmonary edema)&#xD;
&#xD;
          -  Absence of moribund state that would indicate imminent demise and poor chance of&#xD;
             survival.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Females of childbearing potential who are pregnant or unwilling to undergo pregnancy&#xD;
             testing; females with a positive pregnancy test on screening day will be excluded.&#xD;
&#xD;
          -  Breastfeeding mothers&#xD;
&#xD;
          -  Patients on ECMO&#xD;
&#xD;
          -  Receiving concurrent treatment with an investigational agent in a clinical trial.&#xD;
&#xD;
          -  Exception: Use of COVID-19 convalescent plasma is permitted.&#xD;
&#xD;
          -  More than 72hrs on mechanical ventilation before randomization&#xD;
&#xD;
          -  Receiving concurrent investigational vaccine&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lev Verkh, PhD/MS</last_name>
    <role>Study Director</role>
    <affiliation>Stemedica Cell Technologies, Inc.</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Santosh Kesari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Providence Saint John's Health Center - Saint John's Cancer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lev Verkh, PhD/MS</last_name>
    <phone>8586580910</phone>
    <email>lverkh@stemedica.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Providence Saint John's Health Center - Saint John's Cancer Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashley Archer</last_name>
      <phone>310-582-7460</phone>
      <email>ArcherA@jwci.org</email>
    </contact>
    <investigator>
      <last_name>Santosh Kesari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>PRX Research, Dallas Regional Medical Center</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75149</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adeel Shibli, MD</last_name>
      <phone>972-777-4428</phone>
      <email>admin@prxresearch.com</email>
    </contact>
    <investigator>
      <last_name>Adeel Shibli, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 1, 2021</study_first_submitted>
  <study_first_submitted_qc>March 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 3, 2021</study_first_posted>
  <last_update_submitted>March 2, 2021</last_update_submitted>
  <last_update_submitted_qc>March 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

